ARTICLE | Company News
Novo Nordisk, J&J, Innate Pharma deal
June 15, 2015 7:00 AM UTC
Johnson & Johnson’s Janssen Biotech Inc. unit received an exclusive, worldwide license from Novo Nordisk to develop and commercialize anti-NKG2D ( NN8555) for autoimmune indications. Last year, Novo ...